CompletedPhase 3NCT05902598

A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome

Studying Familial chylomicronemia syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Visirna Therapeutics HK Limited
Principal Investigator: Dong YOU, MD., PhD.
Visirna Therapeutics HK Limited
Intervention: Plozasiran(drug)
Enrollment: 37 enrolled
Eligibility: 18 years · All sexes
Timeline: 2023 – 2026

Study locations (1)

Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai Municipality, China

Collaborators

Arrowhead Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05902598 on ClinicalTrials.gov

Other trials for Familial chylomicronemia syndrome

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06471543
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
Ikaria Bioscience Pty Ltd

See all trials for Familial chylomicronemia syndrome →

← Back to all trials